1. Home
  2. SRDX vs DNA Comparison

SRDX vs DNA Comparison

Compare SRDX & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SRDX
  • DNA
  • Stock Information
  • Founded
  • SRDX 1979
  • DNA 2008
  • Country
  • SRDX United States
  • DNA United States
  • Employees
  • SRDX N/A
  • DNA N/A
  • Industry
  • SRDX Medical/Dental Instruments
  • DNA Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • SRDX Health Care
  • DNA Health Care
  • Exchange
  • SRDX Nasdaq
  • DNA Nasdaq
  • Market Cap
  • SRDX 562.6M
  • DNA 562.1M
  • IPO Year
  • SRDX 1998
  • DNA N/A
  • Fundamental
  • Price
  • SRDX $36.88
  • DNA $10.84
  • Analyst Decision
  • SRDX Hold
  • DNA Hold
  • Analyst Count
  • SRDX 4
  • DNA 6
  • Target Price
  • SRDX $43.00
  • DNA $37.80
  • AVG Volume (30 Days)
  • SRDX 276.5K
  • DNA 1.4M
  • Earning Date
  • SRDX 01-30-2025
  • DNA 02-27-2025
  • Dividend Yield
  • SRDX N/A
  • DNA N/A
  • EPS Growth
  • SRDX N/A
  • DNA N/A
  • EPS
  • SRDX N/A
  • DNA N/A
  • Revenue
  • SRDX $126,078,000.00
  • DNA $217,951,000.00
  • Revenue This Year
  • SRDX $13.75
  • DNA N/A
  • Revenue Next Year
  • SRDX $13.67
  • DNA N/A
  • P/E Ratio
  • SRDX N/A
  • DNA N/A
  • Revenue Growth
  • SRDX N/A
  • DNA N/A
  • 52 Week Low
  • SRDX $25.17
  • DNA $5.26
  • 52 Week High
  • SRDX $42.44
  • DNA $64.40
  • Technical
  • Relative Strength Index (RSI)
  • SRDX 34.51
  • DNA 56.55
  • Support Level
  • SRDX $34.76
  • DNA $8.44
  • Resistance Level
  • SRDX $37.08
  • DNA $12.75
  • Average True Range (ATR)
  • SRDX 0.90
  • DNA 1.08
  • MACD
  • SRDX -0.33
  • DNA -0.07
  • Stochastic Oscillator
  • SRDX 38.90
  • DNA 55.68

About SRDX Surmodics Inc.

Surmodics Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The company's mission is to improve the treatment and detection of disease by using its technology to provide solutions to difficult medical devices and diagnostic challenges. It has two reportable segments: Medical device unit; Manufacture of performance coatings, including surface modification coating technologies and the Vitro diagnostics unit; Manufacture of chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets. Surmodics derives majority of its revenue from the Medical Device segment.

About DNA Ginkgo Bioworks Holdings Inc.

Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering and BiosecurityThe majority of revenue in the company comes from the Biosecurity segment, which charges fees for data analytics and services.

Share on Social Networks: